Granules India Ltd Q4 FY25 Earnings Analysis

Published 14 Jun 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹18.2K Cr

Price

766

Market Cap

₹18.2K Cr

P/E Ratio

30.3

Earnings Summary

No information is provided regarding the same in the latest conference call. No information is provided regarding the same in the latest conference call.

📊 Revenue & Sales Performance

No information is provided regarding the same in the latest conference call.

📈 Profitability & Margins

No information is provided regarding the same in the latest conference call.

🏗️ Capital Expenditure Plans

No information is provided regarding the same in the latest conference call.

💰 Fundraising & Capital Structure

No information is provided regarding the same in the latest conference call.

📋 Order Book & Pipeline

No information is provided regarding the same in the latest conference call.

Key Metrics

Frequently Asked Questions

What were Granules India Ltd Q4 FY25 results?

No information is provided regarding the same in the latest conference call. No information is provided regarding the same in the latest conference call.

What is Granules India Ltd share price analysis?

Granules India Ltd currently shows a neutral. The stock trades at a P/E of 30.3 with a market cap of ₹18,243. Investors should review the full earnings analysis for detailed insights.

Is Granules India Ltd planning capital expenditure?

No information is provided regarding the same in the latest conference call.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.

Others in Pharmaceuticals & Biotechnology this season

  • Sun Pharmaceutical Industries Ltd (Q4 FY25)

    Sun Pharmaceutical Industries Ltd Q4 FY25 quarterly results analysis. No information is provided regarding the same in the latest conference call. Market Cap ₹4

  • Sanjivani Paranteral Ltd (Q4 FY25)

    Sanjivani Paranteral Ltd Q4 FY25 quarterly results analysis. No information is provided regarding the same in the latest conference call. Market Cap ₹197, P/E 2

  • IOL Chemicals & Pharmaceuticals Ltd (Q4 FY25)

    IOL Chemicals & Pharmaceuticals Ltd Q4 FY25 quarterly results analysis. - The company anticipates a topline (sales/revenue) growth of around 10% to 12% for FY26

  • Orchid Pharma Ltd (Q4 FY25)

    Orchid Pharma Ltd Q4 FY25 quarterly results analysis. - Orchid Pharma projects approximately 20% volume growth annually based on the past 3 years' CAGR, though